ArticleJCO precision oncology2020
Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer.International journal of cancer · 2026Review
- Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer.Current oncology (Toronto, Ont.) · 2026Review
- Review
- Clinical Validation of Digital PCR-Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Integrating liquid biopsy and mutational signatures to advance precision oncology.NPJ precision oncology · 2026Review
- Current perspectives on circulating tumor DNA in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management.Cancer biology & medicine · 2025Review
- Clinical applications of cell-free DNA-based liquid biopsy analysis.Translational oncology · 2025Article
- Prognostic Role of Circulating DNA in Biliary Tract Cancers: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Prognostic Value of Circulating Tumor DNA in HR+/HER2- Stage I-III Breast Cancer: A Systematic Review.Cancers · 2025Review
- A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer.Breast cancer research : BCR · 2025Article
- Liquid Biopsy in Solid Tumours: An Overview.Cytopathology : official journal of the British Society for Clinical Cytology · 2025Review
- Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy.Nature communications · 2025Article
- The times they are AI-changing: AI-powered advances in the application of extracellular vesicles to liquid biopsy in breast cancer.Extracellular vesicles and circulating nucleic acids · 2025Review
- Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.Cancers · 2024Review
- Use of ctDNA in early breast cancer: analytical validity and clinical potential.NPJ breast cancer · 2024Review
- The prognostic role of circulating tumor DNA across breast cancer molecular subtypes: A systematic review and meta-analysis.Journal of the National Cancer Center · 2024Article
- Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer.Gland surgery · 2024Article
- Article
- Genomic Characteristics and Its Therapeutic Implications in Breast Cancer Patients with Detectable Molecular Residual Disease.Cancer research and treatment · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMany patients with breast cancer still relapse after curative treatment. How to identify the ones with high relapse risk remains a critical problem. Circulating tumor DNA (ctDNA) has recently become a promising marker to monitor tumor burden. Whether ctDNA can be used to predict the response and prognosis in patients with breast cancer receiving neoadjuvant chemotherapy (NAC) is unknown. Our study aimed to evaluate the clinical value of the presence and dynamic change of ctDNA to predict the tumor response and prognosis in patients with breast cancer treated with NAC. MATERIALS AND
methodsFifty-two patients with early breast cancer who underwent NAC were prospectively enrolled. Serial plasma samples before, during, and after NAC and paired tumor biopsies were harvested and subjected to deep targeted sequencing using a large next-generation sequencing panel that covers 1,021 cancer-related genes.
resultsPositive baseline ctDNA was detected in 21 of 44 patients before NAC. Most patients with positive ctDNA had one or more mutations confirmed in paired primary tumor. The ctDNA level after 2 cycles of NAC was predictive of local tumor response after all cycles of NAC (area under the curve, 0.81; 95% CI, 0.61 to 1.00). ctDNA tracking during NAC outperformed imaging in predicting the overall response to NAC. More importantly, positive baseline ctDNA is significantly associated with worse disease-free survival (
conclusionOur study demonstrated that ctDNA can be used to predict tumor response to NAC and prognosis in early breast cancer, providing information to tailor an individual's therapeutic regimen.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.